Localized interleukin-12 delivery for immunotherapy of solid tumours

Area of Science:

• Immunology
• Cancer Biology
• Gene Therapy

Background:

• Interleukin (IL)-12 is a key cytokine for initiating T-helper 1 (Th1) immune responses.
• IL-12 has demonstrated anti-cancer potential, but clinical applications are limited by severe toxicity.
• Gene therapy using lentiviral vectors offers a novel approach to deliver IL-12 for cancer treatment.

Purpose of the Study:

• To evaluate the efficacy of lentiviral vector-mediated IL-12 delivery using autologous tumor cell vaccines in a solid tumor model.
• To investigate the impact of IL-12-producing tumor cell concentration on therapeutic outcomes.
• To determine the immunological mechanisms underlying IL-12 mediated anti-tumor effects.

Main Methods:

• SCCVII tumor cells were transduced with lentiviral vectors to produce varying concentrations of IL-12.
• Transduced and parental SCCVII cells were used to create tumor cell vaccines for subcutaneous injection in mice.
• Tumor growth, clearance, and immune responses were monitored. Depletion antibodies were used to assess the roles of CD4+ and CD8+ T cells.

Main Results:

• A mixture of IL-12-producing and non-producing SCCVII cells resulted in tumor clearance, unlike parental SCCVII cells alone.
• Tumor clearance was achieved with small amounts of high IL-12-producing cells, but not large amounts of low producers, despite equal total IL-12 levels.
• Immunization with IL-12-producing cells induced local and systemic immunity against SCCVII challenge, dependent on CD4+ and CD8+ T cells.

Conclusions:

• Lentiviral vector-mediated delivery of IL-12 via cancer cells is an effective strategy for activating anti-tumor immunity.
• This approach overcomes the toxicity issues associated with systemic IL-12 administration.
• The study successfully established IL-12-producing cell clones from various solid tumor lines, suggesting broad applicability.